In this context, gene therapies that target RyR2 stabilization, CaMKII inhibition, or calmodulin modulation—originally developed for inherited ventricular arrhythmias—could also help reduce ventricular arrhythmias caused by structural heart disease [95,96,98]. The gene discussed is CAMK2G; the disease is Ventricular arrhythmia.